Financial Snapshot

Revenue
$34.85K
TTM
Gross Margin
-3123.44%
TTM
Net Earnings
-$4.367M
TTM
Current Assets
Q3 2022
Current Liabilities
Q3 2022
Current Ratio
8.14%
Q3 2022
Total Assets
Q3 2022
Total Liabilities
Q3 2022
Book Value
-$6.129M
Q3 2022
Cash
Q3 2022
P/E
-0.1314
Nov 29, 2024 EST
Free Cash Flow
-$522.4K
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2021 2020 2019 2018 2017 2016 2015
Revenue $589.0K $3.672M $451.2K $0.00 $41.83K $33.08K $220.8K
YoY Change -83.96% 713.91% -100.0% 26.45% -85.02%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2021 2020 2019 2018 2017 2016 2015
Revenue $589.0K $3.672M $451.2K $0.00 $41.83K $33.08K $220.8K
Cost Of Revenue $1.119M $3.392M $708.6K $0.00 $14.26K $10.25K $169.1K
Gross Profit -$530.2K $280.5K -$257.4K $0.00 $27.57K $22.83K $51.69K
Gross Profit Margin -90.02% 7.64% -57.04% 65.91% 69.01% 23.41%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2021 2020 2019 2018 2017 2016 2015
Selling, General & Admin $1.885M $1.487M $1.617M $6.322M $1.655M $2.698M $1.503M
YoY Change 26.82% -8.04% -74.43% 282.07% -38.66% 79.47%
% of Gross Profit 530.09% 6001.23% 11815.72% 2907.89%
Research & Development $2.400K
YoY Change
% of Gross Profit
Depreciation & Amortization $93.22K $82.89K $63.98K
YoY Change 12.46% 29.56%
% of Gross Profit 29.56%
Operating Expenses $1.885M $1.487M $1.619M $6.322M $1.655M $2.698M $1.503M
YoY Change 26.82% -8.17% -74.39% 282.07% -38.66% 79.46%
Operating Profit -$2.416M -$1.206M -$1.876M -$6.322M -$1.627M -$2.675M -$1.451M
YoY Change 100.26% -35.71% -70.32% 288.54% -39.17% 84.28%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2021 2020 2019 2018 2017 2016 2015
Interest Expense -$1.693M -$42.49M -$2.198M -$859.3K $724.0K -$4.528M -$1.191M
YoY Change -96.01% 1833.46% 155.74% -218.69% -115.99% 280.09%
% of Operating Profit
Other Income/Expense, Net $0.00 -$23.33K $87.49K $471.5K $11.06K
YoY Change -100.0% -126.67% -81.44% 4163.2%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2021 2020 2019 2018 2017 2016 2015
Pretax Income -$5.505M -$4.057M -$4.600M -$8.129M $2.853M -$6.761M -$2.632M
YoY Change 35.69% -11.8% -43.42% -384.91% -142.2% 156.9%
Income Tax $0.00 $800.00 $800.00 $800.00 $800.00
% Of Pretax Income 0.03%
Net Earnings -$5.505M -$4.057M -$4.609M -$8.130M $2.853M -$6.761M -$2.632M
YoY Change 35.68% -11.98% -43.31% -385.02% -142.19% 156.85%
Net Earnings / Revenue -934.64% -110.47% -1021.5% 6819.29% -20439.75% -1192.17%
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share -$10.68K -$8.143K -$32.91K -$253.1K $182.1K -$635.4K -$286.0K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2021 2020 2019 2018 2017 2016 2015
Cash & Short-Term Investments $9.100K $299.9K $266.6K $14.21K $3.590K $22.64K
YoY Change -96.97% 12.49% 1776.21% 295.82% -84.14%
Cash & Equivalents $9.100K $299.9K $14.21K $3.590K $22.64K $9.510K
Short-Term Investments
Other Short-Term Assets $37.40K $107.4K $12.46K
YoY Change -65.19% 762.28%
Inventory $389.3K $502.1K $264.0K
Prepaid Expenses
Receivables $278.4K $39.41K $0.00 $0.00 $51.51K
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $714.2K $948.9K $543.1K $14.21K $3.590K $22.64K $51.51K
YoY Change -24.73% 74.73% 3721.6% 295.82% -84.14% -56.05%
Property, Plant & Equipment $1.845M $1.923M $2.029M $0.00 $0.00 $0.00
YoY Change -4.07% -5.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $170.0K $170.0K
YoY Change -100.0% 0.0%
Other Assets $7.460K $7.460K
YoY Change 0.0%
Total Long-Term Assets $2.102M $2.100M $2.199M $0.00 $0.00 $0.00
YoY Change 0.09% -4.51%
Total Assets $2.816M $3.049M $2.742M $14.21K $3.590K $22.64K
YoY Change
Accounts Payable $1.035M $807.1K $1.074M $703.5K $488.1K $1.693M $1.943M
YoY Change 28.26% -24.85% 52.64% 44.13% -71.16% -12.87%
Accrued Expenses $1.110M $840.2K $496.8K $372.8K $216.0K $132.4K
YoY Change 32.13% 69.13% 33.26% 72.55% 63.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $2.167M $1.044M $771.0K
YoY Change -100.0% 107.68% 35.34%
Long-Term Debt Due $3.935M $1.153M $778.3K
YoY Change 241.4% 48.09%
Total Short-Term Liabilities $7.704M $4.380M $5.115M $5.324M $3.712M $8.171M $1.943M
YoY Change 75.9% -14.39% -3.92% 43.46% -54.58% 320.6%
Long-Term Debt $916.3K $3.267M $1.887M $0.00 $0.00 $0.00
YoY Change -71.95% 73.14%
Other Long-Term Liabilities $11.10K $81.95K $173.9K $0.00
YoY Change -86.46% -52.87%
Total Long-Term Liabilities $927.4K $3.349M $2.061M $0.00 $0.00 $0.00
YoY Change -72.31% 62.51%
Total Liabilities $8.624M $7.729M $7.176M $5.324M $3.712M $8.171M
YoY Change 11.59% 7.7% 34.78% 43.46% -54.58%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2021 2020 2019 2018 2017 2016 2015
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $573.92 Thousand

About Grapefruit USA, Inc

Grapefruit USA, Inc. engages in the manufacture and distribution of cannabis products. The company is headquartered in Los Angeles, California and currently employs 9 full-time employees. The company went IPO on 2016-06-21. The firm manufactures its product line and distribute it, along with other cannabis products, to all licensed cannabis product businesses. The company owns an ethanol extraction facility in the City of Desert Hot Springs, California. The company owns and operates a Type 6 Ethanol Extraction Plant which removes the essential cannabis compounds, such as THC Distillate, that the Company, and others use, to produce cannabis products. Grapefruit manufactures its Hourglass Time Release THC+CBD-Infused Topical Cream at its Coachillin' facility. Hourglass is the full spectrum THC+ Cannabinoid Topical delivery Cream that provides its users with a full body, synergistic entourage. Its Topical Cream is designed to deliver the full effects of THC combined with a range of cannabinoids for a user's overall health, wellness, and well-being. In addition, its extraction lab produces distillate or Honey Oil from cannabis trim sourced by Grapefruit.

Industry: X-Ray Apparatus & Tubes & Related Irradiation Apparatus Peers: AVENUE THERAPEUTICS, INC. Dermata Therapeutics, Inc. Evoke Pharma Inc KIORA PHARMACEUTICALS INC GREEN HYGIENICS HOLDINGS INC. JOHNSON & JOHNSON One World Products, Inc. NovaBay Pharmaceuticals, Inc. Sonoma Pharmaceuticals, Inc. Stem Holdings, Inc.